These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2457219)

  • 1. PAF inhibitors of microbial origin. Studies on diketopiperazine derivatives.
    Yoshida K; Okamoto M; Shimazaki N; Hemmi K
    Prog Biochem Pharmacol; 1988; 22():66-80. PubMed ID: 2457219
    [No Abstract]   [Full Text] [Related]  

  • 2. Diketopiperazine derivatives, a new series of platelet-activating factor inhibitors.
    Shimazaki N; Shima I; Hemmi K; Tsurumi Y; Hashimoto M
    Chem Pharm Bull (Tokyo); 1987 Aug; 35(8):3527-30. PubMed ID: 3427732
    [No Abstract]   [Full Text] [Related]  

  • 3. PAF inhibitory activity of diketopiperazines: structure-activity relationships.
    Shimazaki N; Shima I; Okamoto M; Yoshida K; Hemmi K; Hashimoto M
    Lipids; 1991 Dec; 26(12):1175-8. PubMed ID: 1819704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor in septic shock.
    Koltai M; Hosford D; Braquet PG
    New Horiz; 1993 Feb; 1(1):87-95. PubMed ID: 7922397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.
    Sallem W; Serradji N; Dereuddre-Bosquet N; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):7999-8013. PubMed ID: 16908170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of platelet activating factor (PAF) antagonists from microbial products. I. Bisdethiobis(methylthio)gliotoxin and its derivatives.
    Okamoto M; Yoshida K; Uchida I; Nishikawa M; Kohsaka M; Aoki H
    Chem Pharm Bull (Tokyo); 1986 Jan; 34(1):340-4. PubMed ID: 2421923
    [No Abstract]   [Full Text] [Related]  

  • 7. Paf-acether (platelet-activating factor).
    Benveniste J
    Bull Eur Physiopathol Respir; 1986; 22 Suppl 7():91-4. PubMed ID: 3955269
    [No Abstract]   [Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
    J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological alterations of blood platelets induced by platelet activating factor (PAF) and partial inhibition by ketoprofen in calves.
    Bastos da Silva M; Dessy C; David JL; Lekeux P
    Vet Res; 1997; 28(5):489-502. PubMed ID: 9342825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
    Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
    J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of platelet activating factor (PAF) antagonists from microbial products. III. Pharmacological studies of FR-900452 in animal models.
    Okamoto M; Yoshida K; Nishikawa M; Hayashi K; Uchida I; Kohsaka M; Aoki H
    Chem Pharm Bull (Tokyo); 1986 Jul; 34(7):3005-10. PubMed ID: 3769104
    [No Abstract]   [Full Text] [Related]  

  • 12. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
    Serradji N; Bensaid O; Martin M; Sallem W; Dereuddre-Bosquet N; Benmehdi H; Redeuilh C; Lamouri A; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):8109-25. PubMed ID: 16893650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation].
    Lakin KM; Kulikov VI; Manevich EM; Muliar AG; Shvets VI
    Farmakol Toksikol; 1988; 51(4):113-23. PubMed ID: 2847936
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
    Balsa D; Merlos M; Giral M; Ferrando R; Garcia-Rafanell J; Forn J
    Drugs Exp Clin Res; 1997; 23(5-6):191-9. PubMed ID: 9515229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet activating factor and its role in trauma, shock, and sepsis.
    Ayala A; Chaudry IH
    New Horiz; 1996 May; 4(2):265-75. PubMed ID: 8774801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of PAF antagonists in experimental models. Therapeutical perspectives].
    Desquand S
    Therapie; 1993; 48(6):585-97. PubMed ID: 8091344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N; Martin M; Bensaid O; Cisternino S; Rousselle C; Dereuddre-Bosquet N; Huet J; Redeuilh C; Lamouri A; Dong CZ; Clayette P; Scherrmann JM; Dormont D; Heymans F
    J Med Chem; 2004 Dec; 47(25):6410-9. PubMed ID: 15566310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry of PAF antagonists.
    Godfroid JJ; Heymans F
    Prog Biochem Pharmacol; 1988; 22():25-34. PubMed ID: 3043433
    [No Abstract]   [Full Text] [Related]  

  • 19. Thromboxane rather than platelet activating factor mediates pulmonary vasoconstriction after antigen challenge in rabbits.
    Enzan K; Kurosawa S; Yoshioka N; Inaba H
    Shock; 1996 Sep; 6(3):183-7. PubMed ID: 8885083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.